Adenovirus oncolítico como estrategia de tratamiento en cáncer de seno

Vista sencilla de ítem
dc.contributor.advisorGuerrero Rojas, Rafael Antonio
dc.contributor.authorOrtega Ortega, Karen Michelle
dc.contributor.authorSáenz Gnecco, Sarah Andrea
dc.contributor.authorAparicio Camacho, David Ricardo Antonio
dc.contributor.authorSarmiento Pachón, Paula Alejandra
dc.contributor.authorPolanco Rudd, Laura
dc.date.accessioned2024-05-28T01:39:24Z
dc.date.available2024-05-28T01:39:24Z
dc.date.issued2024-04
dc.description.abstractEl cáncer de mama sigue representando un importante desafío de salud pública debido a su elevada morbilidad, mortalidad, incidencia y los considerables costos asociados. Aunque se han registrado mejoras en la tasa de supervivencia gracias a enfoques terapéuticos integrales, el tratamiento del cáncer de mama en etapas avanzadas o en casos recurrentes sigue siendo un área crítica que requiere atención.En ese sentido, se ha despertado un gran interés en explorar alternativas terapéuticas como los virus oncolíticos, entre los que se destaca el adenovirus tipo 5 (Ad5). Estudios preclínicos y algunos ensayos clínicos han demostrado resultados prometedores en términos de eficacia y seguridad de esta terapia. Sin embargo, es importante señalar que aún se necesita más evidencia clínica para respaldar su uso generalizado. La presente revisión tiene como objetivo ofrecer una actualización exhaustiva sobre el uso del adenovirus oncolítico en el tratamiento del cáncer de mama. Se explorarán en detalle los mecanismos moleculares de acción del virus y se evaluará su efectividad como terapia combinada, especialmente en sinergia con otros tratamientos como cirugía, quimioterapia, radioterapia o inmunoterapia. Se discutirá también el potencial del adenovirus como agente inmunoterapéutico, así como las posibles combinaciones terapéuticas que podrían mejorar aún más los resultados clínicos en pacientes con cáncer de mama en diferentes etapas de la enfermedad. Asi mismo, los avances recientes en el campo, incluyendo ensayos clínicos en fase I y II que emplean adenovirus modificados genéticamente, lo que genera un gran optimismo respecto a su eficacia. Sin embargo, se analizarán también las posibles limitaciones y desafíos que deben superarse para que esta terapia se convierta en una opción viable en la práctica clínica y contribuya significativamente a mejorar el manejo global del cáncer de mama.
dc.description.abstractenglishBreast cancer continues to represent a major public health challenge due to its high morbidity, mortality, incidence and the considerable associated costs. Although there have been improvements in survival rates due to comprehensive therapeutic approaches, the treatment of breast cancer in advanced stages or in recurrent cases remains a critical area that requires attention.In this regard, there is great interest in exploring therapeutic alternatives such as oncolytic viruses, among which adenovirus type 5 (Ad5) stands out. Preclinical studies and some clinical trials have shown promising results in terms of efficacy and safety of this therapy. However, it is important to note that more clinical evidence is needed to support its widespread use. The present review aims to provide a comprehensive update on the use of oncolytic adenovirus in the treatment of breast cancer. The molecular mechanisms of action of the virus will be explored in detail and its effectiveness as a combination therapy will be evaluated, especially in synergy with other treatments such as surgery, chemotherapy, radiotherapy or immunotherapy. The potential of adenovirus as an immunotherapeutic agent, as a possible therapeutic combinations that could further improve clinical outcomes in breast cancer patients at different stages of the disease will also be discussed, as it has been seen in recent advances in the phase I and II clinical trials that using genetically modified adenoviruses generate great optimism regarding their efficacy. Nevertheless, the possible limitations and challenges that must be faced in order for this therapy to become a viable option in clinical practice and contribute significantly in the improvement of the global management of breast cancer will also be discussed.
dc.description.degreelevelPregradospa
dc.description.degreenameMédico Cirujanospa
dc.format.mimetypeapplication/pdf
dc.identifier.instnameinstname:Universidad El Bosquespa
dc.identifier.reponamereponame:Repositorio Institucional Universidad El Bosquespa
dc.identifier.repourlrepourl:https://repositorio.unbosque.edu.co
dc.identifier.urihttps://hdl.handle.net/20.500.12495/12201
dc.language.isoes
dc.publisher.facultyFacultad de Medicinaspa
dc.publisher.grantorUniversidad El Bosquespa
dc.publisher.programMedicinaspa
dc.relation.referencesInternational Agency for Research on Cancer. Estimated number of new cases in 2020, worldwide, both sexes, all ages [internet]. Cancer today. 2020 [citado 07 Abr 2021]. Disponible en: https://gco.iarc.fr/today/online-analysis-table?v=2020&mode=cancer&mode_populati on=continents&population=900&populations=900&key=asr&sex=0&cancer=39&type =0&statistic=5&prevalence=0&population_group=0&ages_group%5B%5D=0&ages_ group%5B%5D=17&group_cancer=1&include_nmsc=1&include_nmsc_other=1 .
dc.relation.referencesSanchez J. OPS/OMS | Cáncer de mama [Internet]. Pan American Health Organization / World Health Organization. 2021 [cited 07 2021]. Disponible en: https://www3.paho.org/hq/index.php?option=com_content&view=article&id=5041:2011-breast-cancer &Itemid=3639&lang=es.
dc.relation.referencesSanchez J. OPS/OMS | Cáncer de mama [Internet]. Pan American Health Organization / World Health Organization. 2021 [cited 07 2021]. Disponible en: https://www3.paho.org/hq/index.php?option=com_content&view=article&id=5041:2011-breast-cancer &Itemid=3639&lang=es.
dc.relation.referencesMinisterio de Salud. Informe del evento: cáncer de mama y cuello uterino [internet]. Colombia: Instituto nacional de salud; 2018 p. 5. Disponible en: https://www.ins.gov.co/buscador-eventos/Informesdeevento/C%C3%81NCER%20DE%20MAMA%20Y%20CUELLO%20UTERINO_2018.pdf.
dc.relation.referencesAmerican Cancer Society. Tasas de supervivencia del cáncer de seno. Actualización más reciente: febrero 9, 2021 . [Consultado 13 de Agosto del 2021]. Disponible en: https://www.cancer.org/es/cancer/cancer-de-seno/comprension-de-un-diagnostico-de-cancer-de-seno/tasas-de-supervivencia-del-cancer-de-seno.html.
dc.relation.referencesMcDonald ES, Clark AS, Tchou J, Zhang P, Freedman GM. Clinical Diagnosis and Management of Breast Cancer. J Nucl Med. febrero de 2016;57(Supplement 1):9S-16S.
dc.relation.referencesPérez Gutiérrez Oscar Alberto, Montejo Viamontes Narciso, Jorge Lázaro Loys, Castro Cruz Rafael, Estrada González Amauris. Análisis de las recidivas locorregionales por cáncer de mama. Rev Cubana Cir [Internet]. 2012 Dic [citado 07 Abr 2021] ; 51( 4 ): 280-287. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0034-74932012000400003&lng=es.
dc.relation.referencesSpinetti Demián, Betancourt Luis, Martínez Pedro, Romero Gabriel, Díaz Felipe, Sánchez Renata et al . Cáncer de mama: Recurrencias locales y regionales múltiples en el tiempo sin extensión sistémica. Rev. Venezuela. oncol. [Internet]. 2009 Dic [citado 2021 Mayo 27] ; 21( 4 ): 225-228. Disponible en: http://ve.scielo.org/scielo.php?script=sci_arttext&pid=S0798-05822009000400006&
dc.relation.referencesCastillo S del, Valfré R, Castillo A del, Gorostiaga B, Pierotti E, Martellotto G, et al. Segunda cirugía conservadora ante una recidiva local del cáncer de mama. Rev argentina mastología. 2018;37:19-30.
dc.relation.referencesRamírez-Torres N, Reyes-López A, Hernández-Valencia M. Asociando factores pronósticos con resultados clínicos en cáncer de mama localmente avanzado. Rev Med Inst Mex Seguro Soc. 2023;61(1):88-98.
dc.relation.referencesPérez Gutiérrez Oscar Alberto, Montejo Viamontes Narciso, Jorge Lázaro Loys, Castro Cruz Rafael, Estrada González Amauris. Análisis de las recidivas locorregionales por cáncer de mama. Rev Cubana Cir [Internet]. 2012 Dic [citado 2024 Mar 10] ; 51( 4 ): 280-287. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0034-74932012000400003&lng=es.
dc.relation.referencesBreast cancer recurrence. Breast cancer recurrence is dependent on (a) disease subtype and (b) stage at diagnosis. a Is reproduced under open access Crown Copyright Oxford University Press from Fig. 2E of Copson et al. 20132 . b Is reproduced with permission from RightsLink from Fig. 2B of Pan et al. 20173.
dc.relation.referencesRuiz S, Navarro B, Prieto V, Yuste MJ. Efecto del tratamiento de radioterapia en el hombro homolateral en mujeres intervenidas de cáncer de mama. Rev Fisiología [internet]. 2018 Feb [citado 26 Mayo 2021]; 40 (1): 19-25. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S0211563817301074.
dc.relation.referencesMartínez AA. Proyecto educativo para familiares de pacientes con cáncer de mama y cuidados respecto a la quimioterapia. [Internet]. [Madrid]: Universidad Pontificia Comillas; 2018 [citado 27 de mayo de 2021]. Disponible en: https://repositorio.comillas.edu/xmlui/bitstream/handle/11531/35808/PFG000896.pdf?sequence=1&isAllowed=y.
dc.relation.referencesVivar CG. Impacto psicosocial del cáncer de mama en la etapa de larga supervivencia: Propuesta de un plan de cuidados integral para supervivientes. Atención primaria. 2010;44(5):288-292. [Consultado 13 de Agosto del 2021] Disponible en: https://www.elsevier.es/es-revista-atencion-primaria-27-articulo-impacto-psicosocial-el-cancer-mama-S0212656711004264.
dc.relation.referencesGao J, Mese K, Bunz O, Ehrhardt A. State-of-the-art human adenovirus vectorology for therapeutic approaches. FEBS Letters. 2019;593(24):3609-22.
dc.relation.referencesGuerrero-Fonseca CA, López-Baquero MA, Bedoya-Rodríguez AA.Virus Oncolíticos: Un Arma Contra el Cáncer. Rev. Fac. Med; 2019. 67 (2); 313-24. [Consultado 13 de Agosto del 2021] . Disponible en: http://www.scielo.org.co/pdf/rfmun/v67n2/0120-0011-rfmun-67-02-313.pdf.
dc.relation.referencesArab A, Behravan N, Razazn A, Barati N, Mosaffa F, Nicastro J, et al. The viral approach to breast cancer immunotherapy. Journal of Cellular Physiology. 2019;234(2):1257-67.
dc.relation.referencesNiemann J, Kühnel F. Oncolytic viruses: Adenoviruses. Virus Genes. 2017;53(5):700-706. [Consultado 13 de Agosto del 2021] Disponible en: https://link.springer.com/article/10.1007/s11262-017-1488-1.
dc.relation.referencesSakhawat A, Ma L, Muhammad T, Khan AA, Chen X, Huang Y. A tumor targeting oncolytic adenovirus can improve therapeutic outcomes in chemotherapy resistant metastatic human breast carcinoma. Scientific Reports. 16 de mayo de 2019;9(1): 7504.
dc.relation.references¿Qué es el cáncer de mama? [Internet]. Breastcancer.org. 2018 [citado 29 de octubre de 2021]. Disponible en: https://www.breastcancer.org/es/sintomas/cancer_de_mama/que_es_cancer_mama.
dc.relation.referencesÁlvarez Hernández C, Vich Pérez P, Brusint B, Cuadrado Rouco C, Díaz García N, Robles Díaz L. Actualización del cáncer de mama en Atención Primaria (III/V). Semergen. 1 de noviembre de 2014;40(8):460-72.
dc.relation.referencesEstadificación del cáncer [Internet]. American Cancer Society. 2015 [citado 29 de octubre de 2021]. Disponible en: https://www.cancer.org/es/tratamiento/como-comprender-su-diagnostico/estadificaciondelcancer.html.
dc.relation.references¿Cómo se origina el cáncer de seno? [Internet]. American Cancer Society. [citado 29 de octubre de 2021]. Disponible en: https://www.cancer.org/es/cancer/cancer-de-seno/acerca/como-se-forma-el-cancer-de-seno.html.
dc.relation.referencesShiovitz S, Korde LA. Genetics of breast cancer: a topic in evolution. Ann Oncol. julio de 2015;26(7):1291-9.
dc.relation.referencesInstituto Nacional de Cancerología ESE. Guía práctica clínica para la detección temprana, tratamiento integral, seguimiento y rehabilitación del cáncer de mama. Instituo Nacional de Cancerología. Colombia.Citado 29 octubre 2021, disponible en: https://www.minsalud.gov.co/sites/rid/1/Gu%C3%ADa%20de%20Pr%C3%A1ctica%20Cl%C3%ADnica%20%20de%20Cancer%20de%20Mama%20versi%C3%B3n%20completa.pdf.
dc.relation.referencesHayes JD, Dinkova-Kostova AT, Tew KD. Oxidative Stress in Cancer. Cancer Cell. 10 de agosto de 2020;38(2):167-97.
dc.relation.referencesOssa CA, Torres D. Founder and Recurrent Mutations in BRCA1 and BRCA2 Genes in Latin American Countries: State of the Art and Literature Review. Oncologist. julio de 2016;21(7):832-9.
dc.relation.referencesAnstey EH, Shoemaker ML, Barrera CM, O’Neil ME, Verma AB, Holman DM. Breastfeeding and Breast Cancer Risk Reduction: Implications for Black Mothers. American Journal of Preventive Medicine. 1 de septiembre de 2017;53(3, Supplement 1):S40-6.
dc.relation.referencesHorn J, Vatten LJ. Reproductive and hormonal risk factors of breast cancer: a historical perspective. Int J Womens Health. 27 de abril de 2017;9:265-72.
dc.relation.referencesLigibel JA, Basen-Engquist K, Bea JW. Weight Management and Physical Activity for Breast Cancer Prevention and Control. American Society of Clinical Oncology Educational Book. 1 de mayo de 2019;(39):e22-33.
dc.relation.referencesMartín de Civetta MT, Civetta JD. Carcinogénesis. Salud Publica Mex. octubre de 2011;53(5):405-14. [citado 17 de noviembre de 2021] Disponible en: http://www.scielo.org.mx/pdf/spm/v53n5/a08v53n5.pdf.
dc.relation.referencesCatherine Sánchez N. Conociendo y comprendiendo la célula cancerosa: Fisiopatología del cáncer. Revista Médica Clínica Las Condes. 2013;24(4):553-562. doi: https://doi.org/10.1016/S0716-8640(13)70659-X..[citado 17 de noviembre de 2021] Disponible en: https://www.sciencedirect.com/science/article/pii/S071686401370659X.
dc.relation.referencesBombonati A, Sgroi DC. The molecular pathology of breast cancer progression. J Pathol. 2011 Jan;223(2):307-17. doi: 10.1002/path.2808.
dc.relation.referencesEllis, M. J. et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature 486, 353–360 (2012).
dc.relation.referencesHu M, Yao J, Cai L, Bachman KE, van den Brûle F, Velculescu V, et al. Distinct epigenetic changes in the stromal cells of breast cancers. Nat Genet. agosto de 2005;37(8):899-905.
dc.relation.referencesSoysal SD, Tzankov A, Muenst SE. Role of the Tumor Microenvironment in Breast Cancer. Pathobiology. septiembre de 2015;82(3-4):142-52.
dc.relation.referencesWong CC-L, Gilkes DM, Zhang H, Chen J, Wei H, Chaturvedi P, et al. Hypoxia-inducible factor 1 is a master regulator of breast cancer metastatic niche formation. Proceedings of the National Academy of Sciences. 27 de septiembre de 2011;108(39):16369-74.
dc.relation.referencesKessenbrock K, Plaks V, Werb Z. Matrix Metalloproteinases: Regulators of the Tumor Microenvironment. Cell. 2 de abril de 2010;141(1): 52-67.
dc.relation.referencesMomeni Movahed Z, Salehiniya H. Epidemiological characteristics of and risk factors for breast cancer in the world. Breast Cancer (Dove Med Press). 10 de abril de 2019;11:151-64.
dc.relation.referencesFerlay J, Soerjomataram I, Dikshit R, et al (2015). Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer, 136, E359-E86.
dc.relation.referencesCáncer de mama. Organización mundial de la salud. Citado 04 Nov 2021. Disponible en: https://www.who.int/es/news-room/fact-sheets/detail/breast-cáncer.
dc.relation.referencesDeSantis CE, Ma J, Goding Sauer A, Newman LA, Jemal A. Breast cancer statistics, 2017, racial disparity in mortality by state. CA Cancer J Clin. 2017 Nov; 67(6):439-448.
dc.relation.referencesDíaz S, Ceballos CW, Perry F, Suárez CAP, Ochoa AMC, Rivera JMB, et al. Educación en Colombia para la detección temprana del cáncer de mama. Revista Colombiana de Cirugía. 13 de diciembre de 2019;34(4):329-37.
dc.relation.referencesGrass MC, Mayorga W. Una visión del cáncer de seno en Colombia. Fasecolda. 2019;6.
dc.relation.referencesRahman SA, Al-Marzouki A, Otim M, Khayat N, Yousef R, Rahman P. Awareness about Breast Cancer and Breast Self-Examination among Female Students at the University of Sharjah: A Cross-Sectional Study [Internet]. Asian Pac J Cancer Prev. 2019; 20(6): 1901-1908. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7021607/.
dc.relation.referencesSultania, M., Kataria, K., Srivastava, A. et al. Validation of Different Techniques in Physical Examination of Breast. Indian J Surg 79, 219–225. https://doi.org/10.1007/s12262-016-1470-5; 2019.
dc.relation.referencesWorld Health Organization. WHO Position Paper on Mammography Screening, 2014. Disponible en: www.paho.org/cancer.
dc.relation.referencesTabar L, Dean PB.Teaching Atlas of Mammography. 3a edición. Thieme; 2011. https://eds-b-ebscohost-com.ezproxy.unbosque.edu.co/eds/ebookviewer/ebook?sid= 8c531fe2-2abf-43b4-ad81-ace69e220d4b%40sessionmgr101&ppid=pp_6&vid=1&for mat=EB.
dc.relation.referencesZeeshan M, Salam B, Khalid Q, Alam S, Sayani R. Diagnostic Accuracy of Digital Mammography in the Detection of Breast Cancer. Cureus [Internet]. 2018 Abril 8; 10 (4). Disponible en:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5991925/.
dc.relation.referencesChong A, Weinstein S, McDonald ES, Conant EF. Digital Breast Tomosynthesis: Concepts and Clinical Practice. ESNA Jor [Internet]. 2019 Mayo 14; 292 (1): 1-14. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6604796/.
dc.relation.referencesSudhir R, Sannapareddy K, Potlapalli A, Krishnamurthy PB, Buddha S, Koppula V. Diagnostic accuracy of contrast-enhanced digital mammography in breast cancer detection in comparison to tomosynthesis, synthetic 2D mammography and tomosynthesis combined with ultrasound in women with dense breast. BJR [Internet]. 2020 Diciembre 02; 94(1118). Disponible en: https://www.birpublications.org/doi/abs/10.1259/bjr.20201046.
dc.relation.referencesGu YL, Pan SM, Ren J, Yang ZX, Jiang GQ. Role of Magnetic Resonance Imaging in Detection of Pathologic Complete Remissión in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: A Meta-analysis. Clin Brea Can [Internet]. 2017 Julio; 17(4): 245-255. Disponible en: https://www.sciencedirect.com/science/article/pii/S1526820916302567.
dc.relation.referencesHarbeck N, Penault-Llorca F, Cortés J, Gnant M, Houssami N, Poortmans P, et al. Breast Cancer. Nature Reviews [Internet]; 2019. Disponible en: https://doi.org/10.1038/s41572-019-0111-2.
dc.relation.referencesNicolini A, Ferrari P, Duffy MJ. Prognostic and predictive biomarkers in breast cancer: past, present and future. Elsevier. Seminars in Cancer Biology. 2018; 52 (parte 1): 56-73.
dc.relation.referencesHortobagyi GN, Connolly JL, D’Orsi CJ, Edge SB, Mittendorf EA, Rugo HS, et al. Breast. En: Amin MB, Edge SB, Greene FL, Byrd DR, Brookland RK, Washington MK, et al., editores. AJCC Cancer Staging Manual [Internet]. 8.ª ed.Springer International Publishing; 2017. p. 589-636. Disponible en: http://link.springer.com/10.1007/978-3-319-40618-3_48.
dc.relation.referencesÁlvarez-Hernández C, Brusint B, Vich P, Díaz-García N, Cuadrado-Rouco C, Hernández-García M. Actualización del cáncer de mama en atención primaria (IV/V). Semergen. 1 de enero de 2015;41(1):34-47.
dc.relation.referencesTreatment of Breast Cancer by Stage [Internet]. American Cancer Society. 2019 ]. Disponible en: https://www.cancer.org/cancer/breast-cancer/treatment/treatment-of-breast-cancer-by-stage.html.
dc.relation.referencesMutebi M, Anderson BO, Duggan C, Adebamowo C, Agarwal G, Ali Z, et al. Breast cancer treatment: A phased approach to implementation [Internet]. Cancer ASC Journals; 19 Abril 2020; 126(S10):2365-2378. Disponible en: https://acsjournals.onlinelibrary.wiley.com/doi/full/10.1002/cncr.32910.
dc.relation.referencesNational Cancer Institute. Physician Data Query (PDQ). Breast Cancer Treatment – Health Professional Version. 2019. Disponible en: https://www.cancer.gov/types/breast/hp/breast-treatment-pdq.
dc.relation.referencesProtocolo de Tratamiento basado en Trastuzumab para el Cáncer de Mama que Sobreexpresan el Gen HER2– LEY 20.850. Ministerio de Salud. 2018;24.
dc.relation.referencesAriza Márquez YV, Briceño Balcázar I, Ancízar Aristizábal F. Tratamiento de cáncer de seno y farmacogenética. Rev Colomb Biotecnol. 1 de mayo de 2016;18(1). Disponible en: http://www.revistas.unal.edu.co/index.php/biotecnologia/article/view/57723.
dc.relation.referencesZhou Li, Rueda M, Alkhateeb A. Classification of breast cancer nottingham prognostic index using high-dimensional embedding and residual neural network. Cancers (Basel). Feb 2022; 14(4):934. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8870306/.
dc.relation.referencesBarba D, León-Sosa A, Lugo P, Suquillo D, Torres F, Surre F, et al. Breast cancer, screening and diagnostic tools: All you need to know. Crit Rev Oncol Hematol. enero de 2021;157:103174.
dc.relation.referencesBartlett DL, Liu Z, Sathaiah M, Ravindranathan R, Guo Z, He Y, et al. Oncolytic viruses as therapeutic cancer vaccines. Molecular Cancer. 11 de septiembre de 2013;12(1):103.
dc.relation.referencesFukuhara H, Ino Y, Todo T. Oncolytic virus therapy: A new era of cancer treatment at dawn. Cancer Sci. octubre de 2016;107(10):1373-9.
dc.relation.referencesMaroun J, Muñoz-Alía M, Ammayappan A, Schulze A, Peng K-W, Russell S. Designing and building oncolytic viruses. Future Virol. abril de 2017;12(4):193-213.
dc.relation.referencesLeppard KN. Adenoviruses: Molecular Biology. En: Reference Module in Biomedical Sciences [Internet]. Elsevier; 2014. Disponible en: https://www.sciencedirect.combola/science/article/pii/B9780128012383025253.
dc.relation.referencesUimet D, Hearing P. 3 - Adenovirus Replication. En: Curiel DT, editor. Adenoviral Vectors for Gene Therapy (Second Edition) [Internet]. 2.ª ed. San Diego: Academic Press; 2016. p. 59-84. Disponible en: https://www.sciencedirect.com/science/article/pii/B9780128002766000036.
dc.relation.referencesArnberg N. Adenovirus receptors: implications for targeting of viral vectors. Trends Pharmacol Sci. agosto de 2012;33(8):442-8.
dc.relation.referencesSmith JG, Wiethoff CM, Stewart PL, Nemerow GR. Adenovirus. Curr Top Microbiol Immunol. 2010;343:195-224.
dc.relation.referencesKaplan JM, Armentano D, Scaria A, et al. Novel role for E4 region genes in protection of adenovirus vectors from lysis by cytotoxic T lymphocytes. Journal of Virology. 1999;73(5):4489-4492. doi: 10.1128/JVI.73.5.4489-4492.1999. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC104342/.
dc.relation.referencesCharman M, Herrmann C, Weitzman MD. Viral and cellular interactions during adenovirus DNA replication. FEBS PRESS science publishing by scientists. 2019;593(24):3531-50.
dc.relation.referencesHarrach B. Adenoviruses: General Features. En: Reference Module in Biomedical Sciences [Internet]. Hungary: Elsevier; 2014 . Disponible en: https://www.sciencedirect.com/science/article/pii/B978012801238302523X.
dc.relation.referencesKajon AE, Weinberg JB, Spindler KR. Adenoviruses. En: Reference Module in Biomedical Sciences [Internet]. Elsevier; 2019. Disponible en: https://www.sciencedirect.com/science/article/pii/B9780128012383000866.
dc.relation.referencesJonas RA, Ung L, Rajaiya J, Chodosh J. Mystery eye: Human adenovirus and the enigma of epidemic keratoconjunctivitis. Prog Retin Eye Res. mayo de 2020;76:100826.
dc.relation.referencesYu B, Zhou Y, Wu H, Wang Z, Zhan Y, Feng X, et al. Seroprevalence of neutralizing antibodies to human adenovirus type 5 in healthy adults in China. Journal of Medical Virology. 1 de septiembre de 2012;84(9):1408-14.
dc.relation.referencesKhanal S, Ghimire P, Dhamoon AS. The Repertoire of Adenovirus in Human Disease: The Innocuous to the Deadly. Biomedicines. marzo de 2018;6(1):30.
dc.relation.referencesRyan KJ, Ray CG. Influenza, parainfluenza, virus sincitial respiratorio, adenovirus y otros virus respiratorios. En: Sherris Microbiología médica, 6e [Internet]. 6.a ed. New York, NY: McGraw-Hill Education; 2017. Disponible en: accessmedicina.mhmedical.com/content.aspx?aid=1143532907.
dc.relation.referencesRuuskanen O, Meurman O, Akusja ̈ riv G. 2002. Adenoviruses, p 515–535. In Richman DD, Whitley RJ, Hayden FG (ed), Clinical Virology, 2nd ed. ASM Press, Washington, DC.
dc.relation.referencesMurray PR, Rosenthal KS, Pfaller, Michael A. Microbiología Médica. 9.a ed.Barcelona: Elsevier; 2021. 421-427 p.
dc.relation.referencesMartínez-Flores, Francisco; Jiménez-Orozco, Fausto Alejandro; Villegas-Castrejón, Hilda Biología molecular de los vectores adenovirales Cirugía y Cirujanos, vol. 74, núm. 6, noviembre-diciembre, 2006, pp. 483-493. Academia Mexicana de Cirugía, A.C. Distrito Federal, México. Disponible en: https://www.redalyc.org/pdf/662/66274613.pdf.
dc.relation.referencesSargent KL, Meulenbroek RA, Parks RJ. Activation of adenoviral gene expression by protein IX is not required for efficient virus replication. Journal of Virology. 2004;78(10):5032-5037.doi: 10.1128/JVI.78.10.5032-5037.2004.[citado 17 de noviembre de 2021]. Disponible en https://www.ncbi.nlm.nih.gov/pmc/articles/PMC400331/.
dc.relation.referencesFarley DC, Brown JL, Leppard KN. Activation of the early-late switch in adenovirus type 5 major late transcription unit expression by L4 gene products. Journal of Virology. 2004;78(4):1782-1791. doi: 10.1128/JVI.78.4.1782-1791.2004. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC369502/.
dc.relation.referencesStewart AR, Tollefson AE, Krajcsi P, Yei SP, Wold WS. The adenovirus E3 10.4K and 14.5K proteins, which function to prevent cytolysis by tumor necrosis factor and to down-regulate the epidermal growth factor receptor, are localized in the plasma membrane. Journal of Virology. 1995;69(1):172-181.doi: 10.1128/JVI.69.1.172-181.1995 .. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC188561/.
dc.relation.referencesBaker AT, Greenshields-Watson A, Coughlan L, Davies JA, Uusi-Kerttula H, Cole DK, et al. Diversity within the adenovirus fiber knob hypervariable loops influences primary receptor interactions. Nat Commun. 14 de febrero de 2019;10(1):741.
dc.relation.referencesEhrhardt A, Haase R, Schepers A, Deutsch MJ, Lipps HJ, Baiker A. Episomal vectors for gene therapy. Curr Gene Ther. junio de 2008;8(3):147-61.
dc.relation.referencesHemminki O, Hemminki A. A century of oncolysis evolves into oncolytic immunotherapy. OncoImmunology. febrero de 2016;5(2):e1074377.
dc.relation.referencesYlösmäki E, Cerullo V. Design and application of oncolytic viruses for cancer immunotherapy. Current Opinion in Biotechnology. 1 de octubre de 2020;65:25-36.
dc.relation.referencesBauerschmitz, G. J., Barker, S. D., & Hemminki, A. Adenoviral gene therapy for cancer: from vectors to targeted and replication competent agents (review). International journal of oncology. 2002: 21(6), 1161–1174.
dc.relation.referencesLopes A, Feola S, Ligot S, Fusciello M, Vandermeulen G, Préat V, et al. Oncolytic adenovirus drives specific immune response generated by a poly-epitope pDNA vaccine encoding melanoma neoantigens into the tumor site. J Immunother Cancer. 1 de diciembre de 2019;7(1):174.
dc.relation.referencesLichtenstein DL, Wold WSM. Experimental infections of humans with wild-type adenoviruses and with replication-competent adenovirus vectors: replication, safety, and transmission. Cancer Gene Ther. Diciembre de 2004;11(12):819-29.
dc.relation.referencesYanagawa-Matsuda A, Mikawa Y, Habiba U, Kitamura T, Yasuda M, Towfik-Alam M, et al. Oncolytic potential of an E4-deficient adenovirus that can recognize the stabilization of AU-rich element containing mRNA in cancer cells. Oncology Reports. 1 de febrero de 2019;41(2):954-60.
dc.relation.referencesDávalos-Salas MI, Recillas-Targa F. La Vía Rb/E2f Y La Familia De Proteínas Represoras Polycomb En El Desarrollo De Cáncer. Tip Revista Especializada en Ciencias Químico-Biológicas. 2011;14(1):38-50.
dc.relation.referencesMorley S, MacDonald G, Kirn D, Kaye S, Brown R, Soutar D. The dl1520 virus is found preferentially in tumor tissue after direct intratumoral injection in oral carcinoma. Clin Cancer Res. 2004;10(13):4357-62.
dc.relation.referencesK.R. Rogulski, S.O. Freytag, K. Zhang, J.D. Gilbert, D.L. Paielli, J.H. Kim, C.C. Heise, D.H. Kirn, Cancer Res. 60, 1193–1196 (2000).
dc.relation.referencesChen J. The Cell-Cycle Arrest and Apoptotic Functions of p53 in Tumor Initiation and Progression. Cold Spring Harb Perspect Med. marzo de 2016;6(3):a026104.
dc.relation.referencesCerullo V, Pesonen S, Diaconu I, Escutenaire S, Arstila PT, Ugolini M, et al. Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients. Cancer Res. 1 de junio de 2010;70(11):4297-309.
dc.relation.referencesKuryk L, Vassilev L, Ranki T, Hemminki A, Karioja-Kallio A, Levälampi O, Vuolanto A, Cerullo V, Pesonen S. Toxicological and bio-distribution profile of a GM-CSF-expressing, double-targeted, chimeric oncolytic adenovirus ONCOS-102 - Support for clinical studies on advanced cancer treatment. PLoS One. 2017 Aug 10;12(8):e0182715. doi: 10.1371/journal.pone.0182715.
dc.relation.referencesRojas JJ, Cascallo M, Guedan S, Gros A, Martinez-Quintanilla J, Hemminki A, et al. A modified E2F-1 promoter improves the efficacy to toxicity ratio of oncolytic adenoviruses. Gene Ther. diciembre de 2009;16(12):1441-51.
dc.relation.referencesBernstein V, Ellard SL, Dent SF, Tu D, Mates M, Dhesy-Thind SK, et al. A randomized phase II study of weekly paclitaxel with or without pelareorep in patients with metastatic breast cancer: final analysis of Canadian Cancer Trials Group IND.213. Breast Cancer Res Treat. enero de 2018;167(2):485-93.
dc.relation.referencesOncolytics Biotech. Randomized, Double-blind, Multicenter Two-Stage Adaptive Phase 3 Study of Intravenous Administration of REOLYSIN (Reovirus Type 3 Dearing) in Combination With Paclitaxel and Carboplatin Versus the Chemotherapy Alone in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck Who Have Progressed on or After Prior Platinum-Based Chemotherapy [Internet]. clinicaltrials.gov; 2014 nov . Report No.: NCT01166542. Disponible en: https://clinicaltrials.gov/ct2/show/NCT01166542.
dc.relation.referencesMD MG. IRENE Study: Phase 2 Study of INCMGA00012 and the Oncolytic Virus Pelareorep in Metastatic Triple Negative Breast Cancer [Internet]. clinicaltrials.gov; 2023 feb . Report No.: NCT04445844. Disponible en: https://clinicaltrials.gov/ct2/show/NCT04445844.
dc.relation.referencesCodagenix, Inc. Phase 1 Study of CodaLytic, an Intratumoral Influenza-based Oncolytic Virus, in Patients With Metastatic or Otherwise Inoperable Breast Cancer [Internet]. clinicaltrials.gov; 2022 oct. Report No.: NCT05600582. Disponible en: https://clinicaltrials.gov/ct2/show/NCT05600582.
dc.relation.referencesJavanbakht M, Tahmasebzadeh S, Cegolon L, Gholami N, Kashaki M, Nikoueinejad H, et al. Oncolytic viruses: A novel treatment strategy for breast cancer. Genes & Diseases. 2021; 2352-3042. Disponible en: https://doi.org/10.1016/j.gendis.2021.11.011.
dc.relation.referencesExcoffon K.J.D.A. The coxsackievirus and adenovirus receptor: virological and biological beauty. FEBS letters. 2020:594(12), 1828–1837. https://doi.org/10.1002/1873-3468.13794.
dc.relation.referencesKhuri, F. R., Nemunaitis, J., Ganly, I., Arseneau, J., Tannock, I. F., Romel, L., Gore, M., Ironside, J., MacDougall, R. H., Heise, C., Randlev, B., Gillenwater, A. M., Bruso, P., Kaye, S. B., Hong, W. K., & Kirn, D. H. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nature medicine. 2000: 6(8), 879–885. Disponible en: https://doi.org/10.1038/78638.
dc.relation.referencesRanki, T., Särkioja, M., Hakkarainen, T., von Smitten, K., Kanerva, A., & Hemminki, A. (2007). Systemic efficacy of oncolytic adenoviruses in imaginable orthotopic models of hormone refractory metastatic breast cancer. International journal of cancer. 2007: 121(1), 165–174. Disponible en: https://doi.org/10.1002/ijc.22627.
dc.relation.referencesO’Bryan SM, Mathis JM. CXCL12 Retargeting of an Oncolytic Adenovirus Vector to the Chemokine CXCR4 and CXCR7 Receptors in Breast Cancer. Journal of Cancer Therapy. 7 de junio de 2021;12(6):311-36.
dc.relation.referencesSoliman H, Khambati F, Han HS, Ismail-Khan R, Bui MM, Sullivan DM, et al. A phase-1/2 study of adenovirus-p53 transduced dendritic cell vaccine in combination with indoximod in metastatic solid tumors and invasive breast cancer. Oncotarget. 10 de enero de 2018;9(11):10110-7.
dc.relation.referencesMohammad Shayestehpour, Sharareh Moghim, Vahid Salimi, Somayeh Jalilvand, Jila Yavarian, Bizhan Romani, Talat Mokhtari-Azad (2017). Targeting human breast cancer cells by an oncolytic adenovirus using microRNA-targeting strategy. Virus Research, 240,207-214. DOI:https://doi.org/10.1016/j.virusres.2017.08.016.
dc.relation.referencesWang J, Li Y, Li S, Yao W, Liu X, Zhu Y, et al. Anti-tumor Synergistic Effect of a Dual Cancer-Specific Recombinant Adenovirus and Paclitaxel on Breast Cancer. Frontiers in Oncology [Internet]. 2020 [citado 15 de noviembre de 2022];10. Disponible en: https://www.frontiersin.org/articles/10.3389/fonc.2020.00244.
dc.relation.referencesTingting Q , Yancheng L, Yan D, Lei Z , Yining D , Yanhui S, et al. CXCR7 regulates breast tumor metastasis and angiogenesis in vivo and in vitro. Shanghai, China. Molecular medicine reports. 2018; 17: 3633-3639. doi: 10.3892/mmr.2017.8286.
dc.relation.referencesTang M, Zu C, He A, Wang W, Chen B, Zheng X. Synergistic antitumor effect of adenovirus armed with drosophila melanogaster deoxyribonucleoside kinase and nucleoside analogs for human breast carcinoma in vitro and in vivo. Drug design, development and therapy. 2015;9:3301-3312. doi: 10.2147/DDDT.S81717. [Consultado 18 de Septiembre del 2021] Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/26203222.
dc.relation.referencesYang Yan, Hu Xu, Jiandong Wang, Xin Wu, Wei Wen, Yan Liang, Lingdi Wang, Fengyuan Liu, Xiaohui Du; Inhibition of breast cancer cells by targeting E2F-1 gene and expressing IL15 oncolytic adenovirus. Biosci Rep 31 July 2019; 39 (7): BSR20190384. doi: https://doi.org/10.1042/BSR20190384.
dc.relation.referencesRoth JA. Adenovirus p53 gene therapy. Expert Opin Biol Ther. 2006 Jan;6(1):55-61. doi: 10.1517/14712598.6.1.55. PMID: 16370914.
dc.relation.referencesTseha ST. Role of Adenoviruses in Cancer Therapy. Frontiers in Oncology [Internet]. 2022 [citado 2 de abril de 2023];12. Disponible en: https://www.frontiersin.org/articles/10.3389/fonc.2022.772659.
dc.relation.referencesMach N, Gao J, Schaffarczyk L, Janz S, Ehrke-Schulz E, Dittmar T, et al. Spectrum-Wide Exploration of Human Adenoviruses for Breast Cancer Therapy. Cancers. 29 de mayo de 2020;12(6):1403.
dc.relation.referencesAuer D, Reimer D, Porto V, Fleischer M, Roessler J, Wiedemair A, et al. Expression of coxsackie-adenovirus receptor is related to estrogen sensitivity in breast cancer. Breast Cancer Res Treat. julio de 2009;116(1):103-11.
dc.relation.referencesMese K, Bunz O, Schellhorn S, Volkwein W, Jung D, Gao J, et al. Identification of novel human adenovirus candidates using the coxsackievirus and adenovirus receptor for cell entry. Virol J. diciembre de 2020;17(1):52.
dc.relation.referencesHuang J, LaRocca C, Yamamoto M. Showing the Way: Oncolytic Adenoviruses as Chaperones of Immunostimulatory Adjuncts. Biomedicines. 19 de septiembre de 2016;4(3):23.
dc.relation.referencesTwumasi-Boateng K, Pettigrew JL, Kwok YYE, Bell JC, Nelson BH. Oncolytic viruses as engineering platforms for combination immunotherapy. Nat Rev Cancer. julio de 2018;18(7):419-32.
dc.relation.referencesHall BL, Leronni D, Miyagawa Y, Goins WF, Glorioso JC, Cohen JB. Generation of an oncolytic herpes simplex viral vector completely retargeted to the GDNF receptor GFRα1 for specific infection of breast cáncer cells. IJMS. 2020;21(22). [Consultado 13 de Agosto del 2021] Disponible en: https://www.mdpi.com/1422-0067/21/22/8815/htm.
dc.relation.referencesBergelson JM, Cunningham JA, Droguett G, Kurt-Jones EA, Krithivas A, Hong JS, Horwitz MS, Crowell RL, Finberg RW. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science. 1997 Feb 28;275(5304):1320-3. doi: 10.1126/science.275.5304.1320. PMID: 9036860.
dc.relation.referencesCohen CJ, Shieh JT, Pickles RJ, Okegawa T, Hsieh JT, Bergelson JM. The coxsackievirus and adenovirus receptor is a transmembrane component of the tight junction. Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):15191-6. doi: 10.1073/pnas.261452898. Epub 2001 Dec 4. PMID: 11734628; PMCID: PMC65005.
dc.rightsAttribution 4.0 Internationalen
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess
dc.rights.accessrightshttp://purl.org/coar/access_right/c_abf2
dc.rights.localAcceso abiertospa
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectCáncer de seno
dc.subjectAdenovirus
dc.subjectAdenovirus oncolítico
dc.subjectAgentes neoplásicos
dc.subjectViroterapia oncolítica
dc.subject.keywordsBreast cancer
dc.subject.keywordsbreast gland cancer
dc.subject.keywordsBreast Neoplasm
dc.subject.keywordsOncolytic Virotherapy
dc.subject.keywordsAntineoplastic Agents
dc.subject.keywordsAdenoviridae Infections
dc.subject.keywordsAdenovirus
dc.subject.nlmW100
dc.titleAdenovirus oncolítico como estrategia de tratamiento en cáncer de seno
dc.title.translatedOncolytic adenovirus as a treatment strategy in breast cancer
dc.type.coarhttps://purl.org/coar/resource_type/c_7a1f
dc.type.coarversionhttps://purl.org/coar/version/c_ab4af688f83e57aa
dc.type.driverinfo:eu-repo/semantics/bachelorThesis
dc.type.hasversioninfo:eu-repo/semantics/acceptedVersion
dc.type.localTesis/Trabajo de grado - Monografía - Pregradospa

Archivos

Bloque original
Mostrando 1 - 1 de 1
Miniatura
Nombre:
Trabajo de grado.pdf
Tamaño:
1.71 MB
Formato:
Adobe Portable Document Format
Descargar
Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
1.95 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Medicina